All News
ACR 2016 – Day 2 Highlights
Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.
Read Article
RheumNow Week in Review – 4 November 2016
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Read Article
Bariatric Surgery Thwarts Gout and Hyperuricemia
The rising incidence of gout has been directly linked to the obesity epidemic. The influence of obesity on gout was further tested in a cohort study of obese patients undergoing bariatric surgery as part of the Swedish Obese Subjects (SOS) study.
Read Article
When Cheap Generics Morph Into Expensive Prescriptions
The Wall Street Journal has reported an alarming trend in generic drug pricing that affects many, especially the elderly and those with arthrtis.
Read Article
Prevalence of Inflammatory Bowel Disease Increases
The MMWR has reported that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), previously (1999) had an estimated 1.8 million (0.9%) prevalence. But as of 2015, an estimated 3.1 million (1.3%) of U.S.
Read Article
The RheumNow Week in Review – 28 October 2016
Dr. Jack Cush reviews highlights, news and journal reports from this week at RheumNow.com
Read Article
Seropositivity Increases Mortality Rates in Rheumatoid Arthritis
It has been long known that rheumatoid arthritis is associated with an increased mortality rate, especially in seropositive patients and those with extraarticular manifestations.
Read Article
Inflectra Biosimilar Ships in Late November 2016
Pfizer has announced it will ship its new FDA-approved biosimilar, Inflectra, in late November and that it will be priced at a15 percent discount to current wholesale prices.
Read Article
RheumNow Week in Review – 14 October 2015
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Read Article
RheumNow Week in Review – 7 October 2016
Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.
Read Article
CDC Says Prevalence of Severe Joint Pain is Rising
The October 7th edition of MMWR reports that severe joint pain (SJP) has significantly risen from 10.5 million in 2012 to 27.2% in 2014, based on recent NHIS surveys.
Read Article
Pharma Points Blame at PBMs
A Wall Street Journal article claims that U.S. drugmakers are pointing the blame at the middlemen who also influence drug priciing.
Read Article
Restricting High Price Drugs - A Dangerous Trend?
Who makes billions in profits and millions in bonus monies? PBMs and insurers, thats who.
This week United Healthcare and Express Scripts announced new plans to restrict patient and prescriber access to popular, expensive, albeit FDA-approved, medications and biologics.
Who benefits, who loses?
EMRs Causing Physician Burnout
Researchers suggest that the burden of EHRs could contribute to physician burnout. The findings of a time and motion study are published in Annals of Internal Medicine.
Read Article
RheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read Article
Flares Portend Damage in Rheumatoid Arthritis - Time for a New Strategy?
Disease flares are common in rheumatoid arthritis (RA), often causing patients to seek additional care, if not medication.
The frequency of flares varies amongst studies in different populations. But the consequence of flares has only recently been studied.
Read Article
Cost of Osteoporosis Care in the USA
The 2010 NHANES study suggests that the overall prevalence of osteoporosis (OP) in the USA is ~10% or 10.2 million older adults (> 50 yrs) had osteoporosis.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
Remicade Patent Infringements Denied: Opens Door for New Biosimilars
A U.S. court has affirmed its decision that the patent for Johnson & Johnson's drug Remicade is invalid. This new ruling favors the intent of Celltrion and Pfizer, who are seeking to bring their biosimilar versions of infliximab to market in the near future.
Read Article
RheumNow Week in Review – 5 August 2016
Highlights from this week on RheumNow.com include:
1. Having #RA in addition to solid cancer (breast, lung, prostate, colon) increases mortality rates by 40-50% in elders https://t.co/aitjusmOai
2. The global market for rheumatoid arthritis therapies was $19.9 billion in 2015, expected to reach $21.3B by 2020 https://t.co/d2Sh5C8y9f
3. Half of doctors never heard of MACRA:Medicare Access & CHIP Reauthorization Act. Starts on Jan 1st! https://t.co/eYgWBWCw6y Blog:https://t.co/sRKZSOFyNV
And more!